Stock TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 10:24:24 2024-04-18 am EDT 		5-day change 1st Jan Change
4,978 ILa +0.57% Intraday chart for Teva Pharmaceutical Industries Limited -4.47% +30.48%
04:56pm Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
02:27pm Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • With a P/E ratio at 10.23 for the current year and 9.55 for next year, earnings multiples are highly attractive compared with competitors.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TEVA PHARMACEUTICAL INDUSTRIES LIMITED Stock Teva Pharmaceutical Industries Limited
+30.48% 14.48B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+24.60% 672B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 550B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.63% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 317B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.38% 292B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
B+
NOVARTIS AG Stock Novartis AG
+0.78% 203B
B-
PFIZER, INC. Stock Pfizer, Inc.
-9.69% 144B
C+
AMGEN INC. Stock Amgen Inc.
-6.63% 141B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. TEVA Stock
  5. Ratings Teva Pharmaceutical Industries Limited